StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
36
Publishing Date
2023 - 09 - 05
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 04 - 03
1
2023 - 03 - 22
1
2023 - 03 - 20
1
2023 - 03 - 08
1
2023 - 02 - 01
1
2023 - 01 - 19
1
2023 - 01 - 04
1
2022 - 11 - 28
1
2022 - 10 - 24
1
2022 - 10 - 05
1
2022 - 09 - 26
1
2022 - 08 - 25
1
2022 - 08 - 23
1
2022 - 08 - 15
2
2022 - 08 - 04
1
2022 - 08 - 01
1
2022 - 07 - 26
1
2022 - 05 - 31
1
2022 - 04 - 12
1
2022 - 03 - 30
1
2022 - 03 - 17
1
2022 - 01 - 26
1
2022 - 01 - 24
1
2021 - 11 - 18
1
2021 - 10 - 25
1
2021 - 08 - 09
1
2021 - 07 - 30
1
2021 - 06 - 04
1
2021 - 05 - 12
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2020 - 12 - 08
1
Sector
Commercial services
19
Communications
6
Consumer durables
1
Consumer non-durables
1
Consumer services
1
Distribution services
8
Electronic technology
16
Energy minerals
1
Finance
19
Finance and insurance
1
Health services
43
Health technology
570
Information
1
Manufacturing
21
Mining, quarrying, and oil and gas extraction
2
Miscellaneous
13
N/a
18
Process industries
13
Producer manufacturing
13
Professional, scientific, and technical services
36
Real estate and rental and leasing
14
Retail trade
5
Technology services
8
Transportation
2
Tags
Acquisition
52
Agreement
52
Alzheimer’s
54
Application
60
Biopharma
91
Biotech-beach
52
Biotechnology
58
Business
115
Cancer
141
Ceo
47
Clinical-trials-phase-ii
48
Collaboration
49
Conference
417
Day
52
Disease
139
Drug
79
Earnings
81
Events
149
Fda
74
Financial
336
Financial results
102
Genetown
60
Genomics
45
Global
173
Group
41
Growth
150
Health
107
Management
57
Market
301
Meeting
112
Molecular
71
N/a
2940
Nasdaq
49
Offering
167
One
51
People
86
Pharm-country
60
Pharmaceuticals
111
Phase 2
55
Positive
94
Pre-clinical
44
Preclinical
86
Presentation
85
Program
64
Publication
56
Report
216
Research
209
Results
586
Rosa
42
Services
76
Software
51
Study
80
Technology
56
Test
47
Therapeutics
698
Therapy
77
Treatment
123
Trial
208
Update
183
Year
154
Entities
Acumen pharmaceuticals inc
5
Alzamend neuro inc
1
Baxter international inc.
1
Miromatrix medical inc
11
Panbela therapeutics inc
19
Sanofi
1
Symbols
ABOS
5
ALZN
1
BAX
1
MIRO
11
PBLA
19
SNY
1
SNYNF
1
Exchanges
Nasdaq
36
Nyse
1
Crawled Date
2023 - 09 - 05
1
2023 - 04 - 10
1
2023 - 04 - 06
1
2023 - 04 - 03
1
2023 - 03 - 22
1
2023 - 03 - 20
1
2023 - 03 - 09
1
2023 - 02 - 01
1
2023 - 01 - 19
1
2023 - 01 - 04
1
2022 - 11 - 28
1
2022 - 10 - 24
1
2022 - 10 - 05
1
2022 - 09 - 26
1
2022 - 08 - 25
1
2022 - 08 - 23
1
2022 - 08 - 16
1
2022 - 08 - 15
1
2022 - 08 - 04
1
2022 - 08 - 01
1
2022 - 07 - 26
1
2022 - 05 - 31
1
2022 - 04 - 12
1
2022 - 03 - 30
1
2022 - 03 - 17
1
2022 - 01 - 26
1
2022 - 01 - 24
1
2021 - 11 - 18
1
2021 - 10 - 25
1
2021 - 08 - 09
1
2021 - 07 - 30
1
2021 - 06 - 04
1
2021 - 05 - 12
1
2021 - 04 - 15
1
2021 - 03 - 15
1
2020 - 12 - 08
1
Crawled Time
01:00
2
11:00
1
12:00
2
12:20
1
13:20
1
14:00
5
14:15
1
15:00
4
15:30
1
16:00
1
16:01
1
17:00
2
19:00
1
20:00
3
21:00
1
22:00
6
23:00
3
Source
www.biospace.com
36
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
sector :
Professional, scientific, and technical services
tags :
Biomidwest
save search
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of FlynpoviPatent developed in collaboration with Sanofi
Published:
2023-09-05
(Crawled : 20:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-98.19%
|
O:
1.38%
H:
4.76%
C:
-0.68%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-14.53%
|
O:
-0.93%
H:
0.0%
C:
0.0%
patent
collaboration
sanofi
Miromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Med
Published:
2023-04-10
(Crawled : 12:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
118.71%
|
O:
5.81%
H:
1.22%
C:
-0.91%
ceo
cell
meeting
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
Published:
2023-04-06
(Crawled : 14:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-94.66%
|
O:
2.29%
H:
16.42%
C:
6.0%
presentation
endocrine
meeting
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
Published:
2023-04-03
(Crawled : 14:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-96.04%
|
O:
1.76%
H:
2.22%
C:
-7.11%
research
agreement
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Published:
2023-03-22
(Crawled : 14:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-96.7%
|
O:
-1.89%
H:
9.58%
C:
1.92%
sbp-101
patent
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
Published:
2023-03-20
(Crawled : 22:00)
- biospace.com/
ABOS
|
$3.475
-0.71%
-0.72%
150K
|
Professional, Scientific, and T...
|
-9.56%
|
O:
-0.26%
H:
3.35%
C:
-2.85%
report
pharmaceuticals
financial
results
Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum
Published:
2023-03-08
(Crawled : 01:00)
- biospace.com/
ABOS
|
$3.475
-0.71%
-0.72%
150K
|
Professional, Scientific, and T...
|
-35.9%
|
O:
-0.18%
H:
4.04%
C:
1.28%
pharmaceuticals
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
Published:
2023-02-01
(Crawled : 15:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
-2.87%
|
O:
-0.57%
H:
5.19%
C:
-9.8%
BAX
|
News
|
$39.52
-0.13%
0.0%
2.8M
|
Health Technology
|
-13.39%
|
O:
0.44%
H:
1.04%
C:
0.85%
care
research
liver
agreement
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published:
2023-01-19
(Crawled : 17:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-99.48%
|
O:
9.82%
H:
7.86%
C:
-11.11%
sbp-101
designation
ema
gemcitabine
pancreatic
Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
Published:
2023-01-04
(Crawled : 15:00)
- biospace.com/
ABOS
|
$3.475
-0.71%
-0.72%
150K
|
Professional, Scientific, and T...
|
-33.46%
|
O:
-1.33%
H:
7.32%
C:
5.2%
pharmaceuticals
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published:
2022-11-28
(Crawled : 16:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-99.67%
|
O:
5.66%
H:
0.07%
C:
-10.71%
sbp-101
europe
aspire
trial
gemcitabine
pancreatic
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
Published:
2022-10-24
(Crawled : 14:00)
- biospace.com/
ABOS
|
$3.475
-0.71%
-0.72%
150K
|
Professional, Scientific, and T...
|
-54.19%
|
O:
1.44%
H:
3.69%
C:
-1.94%
acu193
fda
designation
disease
alzheimer's
granted
anti-amyloid beta
fast track designation
Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Mesa
Published:
2022-10-05
(Crawled : 23:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
-22.25%
|
O:
-1.15%
H:
1.86%
C:
-5.57%
ceo
meeting
Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
Published:
2022-09-26
(Crawled : 22:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
-3.97%
|
O:
4.53%
H:
4.61%
C:
0.78%
ceo
Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology
Published:
2022-08-25
(Crawled : 12:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
22.83%
|
O:
19.2%
H:
0.0%
C:
-14.29%
patent
technology
Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase
Published:
2022-08-23
(Crawled : 12:20)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
23.27%
|
O:
0.36%
H:
1.09%
C:
-0.36%
growth
Miromatrix Reports Second Quarter 2022 Results and Provides Corporate Update
Published:
2022-08-15
(Crawled : 01:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
22.12%
|
O:
1.22%
H:
0.0%
C:
-1.78%
update
results
Panbela Provides Business Update and Reports Q2 2022 Financial Results
Published:
2022-08-15
(Crawled : 23:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-99.97%
|
O:
0.05%
H:
0.0%
C:
-7.75%
update
results
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Published:
2022-08-04
(Crawled : 17:00)
- biospace.com/
PBLA
|
$0.525
-6.31%
38K
|
Professional, Scientific, and T...
|
-99.97%
|
O:
1.56%
H:
3.05%
C:
-2.3%
sbp-101
trial
gemcitabine
pancreatic
Miromatrix to Report Second Quarter 2022 Financial Results
Published:
2022-08-01
(Crawled : 21:00)
- biospace.com/
MIRO
|
$3.39
3.25%
630K
|
Professional, Scientific, and T...
|
22.38%
|
O:
2.89%
H:
1.75%
C:
-1.75%
report
results
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.